after enrollment, a baseline visit is performed to record the initial skin disease score (clasi-a) and other health measures.

participants are randomly assigned to receive either enpatoran or a matching placebo without knowing which one they receive.

the assigned medication is taken by mouth as a film‑coated tablet.

the dose and frequency are specified in the study protocol and are taken each day for the duration of the trial.

participants continue the daily oral intake of the study tablet for a total of 24 weeks.

the medication may be taken with or without food, as instructed by the study staff.

clinic visits are scheduled at week 4, week 12, and week 24.

at each visit, the skin disease score (clasi-a) is measured again, and other evaluations such as the bicla response and laboratory tests are performed.

the visits also include monitoring for any adverse events, including serious adverse events and events of special interest.

at week 24, the primary goal is to determine whether the participant achieved a clasi-70 response, meaning a reduction of at least 70% from the baseline skin score.

secondary goals, such as the bicla response, corticosteroid reduction, and safety outcomes, are also reviewed.

after the final assessments, the study medication is discontinued and the participant completes the trial.